Ultralow PSA, Treatment Nuance, and the Call for More Equitable Care

Timecodes:

ARANOTE trial- 43:32-48:08

Rationale of using ultra-low PSA thresholds- 48:08-51:25

Understanding the prognostic value of ultra-low PSA results- 51:25-55:20

Ultralow PSA levels in the TITAN trial- 55:20-58:24

Ultralow PSA as a clinical benchmark- 58:24-1:00:48

Benefits of monitoring response with PSA- 1:00:48-1:01:32

Implications of suboptimal PSA response- 1:01:32-1:05:41

Selection of AR-targeted therapies- 1:05:41-1:07:30

Disparities in trial outcomes- 1:07:30-1:10:48

Improving disparities through changes in practice- 1:10:48-1:13:32